share_log

Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study

Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study

y-mabs therapeutics的神经母细胞瘤药物在临床研究中显示出一致的疾病控制
MT Newswires ·  09/06 09:24

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发